123 related articles for article (PubMed ID: 26599532)
1. Extended structure-activity study of thienopyrimidine-based EGFR inhibitors with evaluation of drug-like properties.
Bugge S; Buene AF; Jurisch-Yaksi N; Moen IU; Skjønsfjell EM; Sundby E; Hoff BH
Eur J Med Chem; 2016 Jan; 107():255-74. PubMed ID: 26599532
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.
Bugge S; Kaspersen SJ; Larsen S; Nonstad U; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2014 Mar; 75():354-74. PubMed ID: 24556149
[TBL] [Abstract][Full Text] [Related]
3. Truncated structures used in search for new lead compounds and in a retrospective analysis of thienopyrimidine-based EGFR inhibitors.
Bugge S; Moen IU; Sylte KO; Sundby E; Hoff BH
Eur J Med Chem; 2015 Apr; 94():175-94. PubMed ID: 25768701
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
5. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
Kaspersen SJ; Han J; Nørsett KG; Rydså L; Kjøbli E; Bugge S; Bjørkøy G; Sundby E; Hoff BH
Eur J Pharm Sci; 2014 Aug; 59():69-82. PubMed ID: 24769040
[TBL] [Abstract][Full Text] [Related]
6. Irreversible inhibitors of the epidermal growth factor receptor: thienopyrimidine core with α,β-unsaturated amide side chain.
Yang XL; Wang TC; Lin S; Fan HX
Arch Pharm (Weinheim); 2014 Aug; 347(8):552-8. PubMed ID: 24917121
[TBL] [Abstract][Full Text] [Related]
7. Chiral 6-aryl-furo[2,3-d]pyrimidin-4-amines as EGFR inhibitors.
Han J; Kaspersen SJ; Nervik S; Nørsett KG; Sundby E; Hoff BH
Eur J Med Chem; 2016 Aug; 119():278-99. PubMed ID: 27235841
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Potent Antiproliferative Agents Targeting EGFR Tyrosine Kinase Based on the Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4-amine Scaffold.
Aziz YM; Said MM; El Shihawy HA; Tolba MF; Abouzid KA
Chem Pharm Bull (Tokyo); 2015; 63(12):1015-28. PubMed ID: 26633023
[TBL] [Abstract][Full Text] [Related]
9. Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors.
Han J; Henriksen S; Nørsett KG; Sundby E; Hoff BH
Eur J Med Chem; 2016 Nov; 124():583-607. PubMed ID: 27614407
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 2-aryl-8-hydroxy (or methoxy)-isoquinolin-1(2H)-ones as novel EGFR inhibitor by scaffold hopping.
Kang BR; Shan AL; Li YP; Xu J; Lu SM; Zhang SQ
Bioorg Med Chem; 2013 Nov; 21(22):6956-64. PubMed ID: 24094432
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.
Waterson AG; Petrov KG; Hornberger KR; Hubbard RD; Sammond DM; Smith SC; Dickson HD; Caferro TR; Hinkle KW; Stevens KL; Dickerson SH; Rusnak DW; Spehar GM; Wood ER; Griffin RJ; Uehling DE
Bioorg Med Chem Lett; 2009 Mar; 19(5):1332-6. PubMed ID: 19208477
[TBL] [Abstract][Full Text] [Related]
12. Medicinal Attributes of Thienopyrimidine Based Scaffold Targeting Tyrosine Kinases and Their Potential Anticancer Activities.
Ghith A; Ismail NSM; Youssef K; Abouzid KAM
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 29027246
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells.
Pédeboscq S; Gravier D; Casadebaig F; Hou G; Gissot A; De Giorgi F; Ichas F; Cambar J; Pometan JP
Eur J Med Chem; 2010 Jun; 45(6):2473-9. PubMed ID: 20219270
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
[TBL] [Abstract][Full Text] [Related]
15. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Sundby E; Han J; Kaspersen SJ; Hoff BH
Eur J Pharm Sci; 2015 Dec; 80():56-65. PubMed ID: 26296860
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
[TBL] [Abstract][Full Text] [Related]
18. Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.
Beckers T; Sellmer A; Eichhorn E; Pongratz H; Schächtele C; Totzke F; Kelter G; Krumbach R; Fiebig HH; Böhmer FD; Mahboobi S
Bioorg Med Chem; 2012 Jan; 20(1):125-36. PubMed ID: 22169601
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
20. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
